A retrospective study on the efficacy and safety of Envafolimab, a PD-L1 inhibitor, in the treatment of advanced malignant solid tumors

A retrospective study on the efficacy and safety of Envafolimab, a PD-L1 inhibitor, in the treatment of advanced malignant solid tumors

Envafolimab, a PD-L1 inhibitor, has demonstrated potential in treating advanced malignant solid tumors (AMST). To study its’ efficacy and safety in AMST, our retrospective study recruited 64 patients with various AMST, and treated with Envafolimab (400 mg every 3 weeks). We divided the patients into...

Full description

Bibliographic Details
Main Authors: Congjun Zhang, Jingjing Li, Hongyang Wu, Wei Huang, Liangshan Da, Yuanyuan Shen, Guoping Sun
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-01-01
Series:Frontiers in Pharmacology
Subjects:
Envafolimab
PD-L1 inhibitor
advanced solid tumors
cancer treatment
immunotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2024.1356013/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2024.1356013/full

Similar Items